Gold+
| Address | 6F Haesung-2-Bldg, Teheran-Ro 508, Gangnam-gu, 135-725 Seoul | ||
|---|---|---|---|
| Telephone | 010-6733-0652 | Fax | 02-2185-3939 |
| Website | https://www.merckgroup.com/kr-ko | Sang-gu.seo@merckgroup.com / hyun-jin.kwon@pfizer. | |
"Merck Biopharma Korea founded in 1989 is a Korean subsidiary of Merck which is the oldest pharmaceutical/chemical group with 354 years of history in the world. Merck Biopharma Korea is a healthcare division among three business sectors (healthcare, performance materials and life science) that of Merck Korea which claims to stand for ‘Innovative science and technology leader company’ is operating in Korea. Merck Biopharma Korea continues to grow with the vision ‘creating values for patients and HCPs by developing and supplying innovative medicines’. Especially, we are focusing our efforts on the launch of new specialty pipeline products in line with its strategy to achieve Merck’s global healthcare goal of becoming ‘Global Specialty Innovator.’ It provides therapeutic drugs for immune-oncology, oncology, neurology, immunology, infertility and endocrinology etc and introduces innovative products and technologies that lead the market in specialized fields such as multiple sclerosis, growth hormones and infertility."
“At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Collaborations with healthcare providers, patient communities and academia are fundamental for Pfizer Korea in bringing new medicines to patients. More information on this can be found at Pfizer Cares. Health is a key issue for all Koreans and Pfizer Korea engages with Government to share its extensive knowledge and global perspectives about public health, disease prevention, health education and affordability for the community. To better meet the need of patients, Pfizer contributes to policy discussions across a range of related areas including; • Access to medicines • Efficacy and safety of medicines • Prevention • Important public health priorities such as antimicrobial resistance, and emerging science including gene therapy”
BAVENCIO is anti PD-L1 immunotherapy which has shown in preclinical models to engage both the adaptive and innate immune functions. Bavencio is approved as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum based chemotherapy based on OS prolongation by 7.1 month vs. BSC in JAVELIN bladder 100 study and as monotherapy for treatment of adult patients with metastatic Merkel cell carcinoma
